Announcements

Kimberly Anne Rutledge, Chief People Officer of Q2 Holdings, Inc. (NYSE:QTWO), filed a Form 4 on August 12, 2026, reporting the sale of 10,000 shares of common stock on August 10, 2026, pursuant to a Rule 10b5-1 trading plan.

John T. Hall, Chief Executive Officer and Director of Intapp, Inc. (NASDAQ:INTA), filed a Form 4 on August 12, 2026, disclosing the exercise of employee stock options and the same-day sale of 3,000 shares of common stock on August 10, 2026.

Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc. (NASDAQ:BCAX), filed a Form 4 on August 12, 2026, disclosing the exercise of stock options and the sale of 12,500 shares of common stock on August 10, 2026, pursuant to a Rule 10b5-1 trading plan.

Claire Mazumdar, Chief Executive Officer and Director of Bicara Therapeutics Inc., filed a Form 4 on August 12, 2026, reporting the exercise of stock options and a same-day sale of common stock on August 10, 2026, pursuant to a Rule 10b5-1 trading plan.

Ryan Cohlhepp, President and Chief Operating Officer of Bicara Therapeutics Inc., filed a Form 4 on August 12, 2026, disclosing the exercise of stock options and the sale of 18,750 shares of common stock on August 10, 2026, pursuant to a Rule 10b5-1 trading …

A Form 4 filed on August 12, 2026, discloses that John Dietrich Pauls, President and CEO of DiaMedica Therapeutics Inc. (NASDAQ:DMAC), acquired 60,200 restricted stock units on August 10, 2026, at a price of $0.

A Form 4 filed with the SEC on August 12, 2026 discloses that Axogen, Inc. director Amy McBride-Wendell exercised stock options and sold 13,353 shares of common stock on August 11, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.